The company has developed protease, NS5A, polymerase, and cyclophilin-based inhibitors for the treatment of HCV, as well as macrolide antibiotics to overcome bacterial resistance. Enanta Pharmaceuticals has strategic alliances with Abbott Laboratories and Shionogi & Co., LTD, and has developed two protease inhibitors, glecaprevir and paritaprevir, in collaboration with AbbVie, which have been approved worldwide for the treatment of HCV.